Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
17 participants
INTERVENTIONAL
2023-12-06
2024-01-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Plant-based Polar Lipids on Acute and Second Meal Glucose Tolerance and Appetite Sensations
NCT05844085
Effect of Oat Compounds on Postprandial Glucose Response
NCT05177172
Health Effects of Oat and Oat Polar Lipids in Human
NCT05139355
Effect of Oats on Lipid Profile
NCT02376660
Meta-analysis of Oats for Diabetes Prevention and Management
NCT04631913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Polar lipid 1
15 g Plant polar lip 1 consumed with a white wheat bread including 50 g available carbohydrates
Polar lipid 1
15g plant polar lipids from plant source 1. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
Polar lipid 2
15 g Plant polar lipids 2 consumed with a white wheat bread including 50 g available carbohydrates
Polar lipid 2
15g plant polar lipids from plant source 2. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
non-polar lipids
15 g commonly consumed non-polar lipids consumed with a white wheat bread including 50 g available carbohydrates
Non-polar lipids
15g non-polar plant lipids from plant source 1. The lipids supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
no lipids
A white wheat bread including 50 g available carbohydrates
No lipids
A commercial white wheat flour bread as a source of available carbohydrates (50 g), without added lipids.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polar lipid 1
15g plant polar lipids from plant source 1. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
Polar lipid 2
15g plant polar lipids from plant source 2. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
Non-polar lipids
15g non-polar plant lipids from plant source 1. The lipids supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
No lipids
A commercial white wheat flour bread as a source of available carbohydrates (50 g), without added lipids.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* non-smokers
* between 20-40 years of age
* BMI between 18,5-30 kg/m2
* No known metabolic disorders or food allergies.
* The test subjects should follow a normal diet in accordance with the Nordic Nutrition Recommendations.
Exclusion Criteria
* Use of antibiotics or probiotics in the last three months or during the study period.
* Smoking
* Blood donation during the last two months and during the study.
* Food allergies or food intolerances
* Cardiovascular diseases
* Metabolic diseases
* Inflammatory bowel diseases.
20 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Anne Nilsson
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anne Nilsson
Associate professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lund University, dep of Food Technology, Engineering, and Nutrition
Lund, Välj..., Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Prot.2018/8-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.